ALNYLAM PHARDRNALNYLAM PHARDRNALNYLAM PHARDRN

ALNYLAM PHARDRN

No trades
See on Supercharts
Market capitalization
‪170.38 B‬BRL
−13.340BRL
‪−2.14 B‬BRL
‪8.89 B‬BRL
‪125.77 M‬
Beta (1Y)
0.94

About Alnylam Pharmaceuticals, Inc.

CEO
Yvonne L. Greenstreet
Headquarters
Cambridge
Employees (FY)
‪2.1 K‬
Founded
2002
ISIN
BRA1LNBDR003
FIGI
BBG00XV4BP79
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002 and is headquartered in Cambridge, MA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Curated watchlists where A1LN34 is featured.